Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes! 

Vertex Pharmaceuticals’ latest earnings for the first quarter of 2025 reveals key insights into the company’s financial performance and strategic direction. The company reported total revenue of $2.77 billion, marking a 3% increase compared to the same period in 2024. This growth was primarily driven by strong demand in the U.S., particularly for the cystic fibrosis (CF) treatment ALYFTREK, which gained FDA approval recently. However, international revenue experienced a decline, notably impacted by competition from an illegal product in Russia. Excluding the Russian market issue, international growth would have been positive.